Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
ProVerum Medical is a medtech company that develops novel minimally invasive devices to treat benign prostatic hyperplasia.
ENYO Pharma is a biopharmaceutical company based in Lyon, France.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.
RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Helicore Biopharma is a biopharmaceutical company that discovers and develops novel weight-loss therapeutics.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.
Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.
OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 15 different industry categories.
Among tracked funding rounds, Verdiva Bio received $411.0M in a Series A round. OrbiMed's total known invested capital is $23.6B.
OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.
Recent OrbiMed portfolio additions include ProVerum Medical, ENYO Pharma, Alpheus Medical, RayThera, Garuda Therapeutics. These companies were founded in 2020 or later.